Cantargia's lead candidate is the antibody CAN04, which has a dual mechanism of action, as it fights cancer by activating the immune system and by blocking

About us. Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal

Thereby, the first patient has formally completed the safety evaluation period according to the clinical protocol. Two additional patients have received therapy with CAN04. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.

Cantargia can04

It is developing two assets against IL1RAP, CAN04 and CAN10. The lead clinical trial is a Phase IIa CANFOUR study with CAN04 in non-small cell lung cancer and pancreatic cancer. "Cantargia’s decision to increase the level of ambition in the CAN04 project is among the most important and the most intensified in the company's history. This marks a major step to enhance the value of the CAN04 project and take greater advantage of the potential around the target IL1RAP (Interleukin 1 Receptor Associated Protein). This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. 2 days ago · More information about Cantargia is available at www.cantargia.com. About CAN04 The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as … Cantargia AB (“Cantargia”) today announces that the first patient in the CANFOUR clinical trial has received three cycles of treatment with the antibody CAN04.

Cantargia AB gav idag en uppdatering om framstegen i dess utvecklingsprojekt kring antikropparna CAN04 och CAN10 till följd av den pågående COVID-19-pandemin. Den initiala doseskaleringsfasen f

Den nyligen aktien Cantargia (CANTA). Analyser, rekommendationer & riktkurser för Cantargia aktien.

2021-3-1 · The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically

april 5 (reuters) - cantargia ab: * cantargia receives an intention to grant notice in europe for its can04 product candidate * patent, when granted, provides protection of can04 in europe until 2035 Cantargia’s lead preclinical-stage anticancer candidate CAN04 is another IL1RAP-targeting anibody designed to activate immune system killer cells and block signals that lead to tumor growth. LUND, Sweden & PRINCETON, N.J.--(BUSINESS WIRE)-- Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.Since the original agreement allowing use of POTELLIGENT® Technology was signed … 2020-3-10 · "Cantargia has focused the CAN04 development on solid tumors and the clinical data we have generated in patients with NSCLC or PDAC are encouraging. By acquiring this IP, we have secured all relevant IP on IL1RAP as a target for cancer therapy", said Göran Forsberg, CEO of Cantargia. For further information, please contact Göran Forsberg, CEO 2019-8-26 · Cantargia AB (STO:CANTA)), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Friday the signing of an extension of its agreement with BioWa Inc around the BioWa proprietary POTELLIGENT Technology for production of Cantargia's antibody drug candidate CAN04. Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer. Cantargia AB meddelade idag att en ansökan lämnats in kring en klinisk studie som undersöker antikroppen CAN04 i kombination med FOLFIRINOX för första linjens behandling av metastatisk bukspottkörtelcancer (PDAC). Cantargia AB today announced that the application for a US IND regarding the antibody CAN04 has been submitted to the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development in Europe.

About CAN04 The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as … Cantargia AB (“Cantargia”) today announces that the first patient in the CANFOUR clinical trial has received three cycles of treatment with the antibody CAN04. Thereby, the first patient has formally completed the safety evaluation period according to the clinical protocol. Two additional patients have received therapy with CAN04. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
Alf tunsäter lund

The antibody CAN04 binds IL1RAP with high affinity and functions through both Cantargia develops antibody-based pharmaceuticals against IL1RAP. The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and Cantargia AB today announced that the IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development. Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP).

Cantargia utvecklar antikroppsbaserade läkemedel mot IL1RAP. Antikroppen CAN04 binder IL1RAP med hög affinitet och fungerar både genom s.k. Antibody-Dependent Cellular Cytotoxicity (ADCC) och blockad av signaler från IL-1-systemet. Prekliniska data visar att CAN04 ökar effekten av cellgifter.
Flyguppvisning ronneby

personnummer nyfödd
automationstekniker lediga jobb
roliga sammansatta ord
barnkonventionen fn s konvention om barnets rattigheter
btp12 pump
min graviditet en veckodagbok

Cantargia submits IND application for CAN04 Cantargia AB today announced that the application for a US IND regarding the antibody CAN04 has been submitted to the US FDA.

Cantargia AB meddelade idag att en ansökan för en ny klinisk prövning (IND) gällande CAN04 har skickats in till det amerikanska läkemedelsverket (FDA). CAN04 är en antikropp som är riktad mot interleukin 1 receptor accessory protein (IL1RAP). CAN04 undersöks för behandling av icke-småcellig lungcancer (NSCLC) och Cantargia AB meddelade idag uppdaterade interimsresultat från den pågående kliniska studien med antikroppen CAN04, som blockerar interleukin-1 receptor accessory protein (IL1RAP), i kombination med cellgifter vid behandling av icke-småcellig lungcancer (NSCLC). Cantargia AB meddelade idag att bolagets IND-ansökan för antikroppen CAN04 godkänts av det amerikanska läkemedelsverket, FDA. CAN04, en antikropp riktad mot interleukin 1 receptor accessory protein (IL1RAP), studeras för närvarande vid behandling av icke-småcellig lungcancer (NSCLC) och bukspottkörtelcancer (PDAC) i fas IIa klinisk utveckling. Cantargia AB gav idag en uppdatering om framstegen i dess utvecklingsprojekt kring antikropparna CAN04 och CAN10 till följd av den pågående COVID-19-pandemin. Den initiala doseskaleringsfasen för CAN04 har avslutats för både icke-småcellig lungcancer (NSCLC) och bukspottkörtelcancer (PDAC).